Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease

Restrepo, Ruben D; Tate, A. K.; Coquat, Joshua

doi:10.1517/14656566.2013.823949

Cited by 3 publications

(3 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Salmeterol, a β2-receptor agonist, is recommended as a long-acting bronchodilator for patients with COPD (36). Restrepo et al (8) identified that salmeterol xinafoate and fluticasone propionate treatment improved the survival rate of patients with severe COPD. In addition, Ryan et al (37) indicated that salmeterol also improved nocturnal sleeping arterial oxygen saturation and sleep quality.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of salmeterol and formoterol combination treatment in mice with chronic obstructive pulmonary disease

Wang

Yang

2017

Exp Ther Med

View full text Add to dashboard Cite

Abstract. Chronic obstructive pulmonary disease (COPD) is a severe lung disease characterized by progressive airflow limitation. Salmeterol and formoterol are two commonly used drugs in COPD therapy, which act as β2-receptor agonists. In the current study, a mouse model of COPD induced by airway lipopolysaccharide inhalation was established. The therapeutic efficacy of salmeterol and formoterol co-treatment was investigated in this model over a 56-day-long observation period. It was also identified that functional residual capacity and inspiratory resistance were significantly improved after salmeterol and/or formoterol treatment compared with the control group (all P<0.01). Furthermore, histological staining of lung tissue samples indicated that inflammation, thickening of the smooth muscle, goblet cell hyperplasia and pulmonary small vessel obstruction were reduced in the mice treated with salmeterol and/or formoterol, suggesting that salmeterol and formoterol were beneficial for ongoing airway and blood vessel remodeling in mice with COPD. The most common treatment-associated adverse events were hypertension and proteinuria. In conclusion, combined salmeterol and formoterol treatment was more effective compared with either single agent, suggesting that salmeterol and formoterol combined treatment has therapeutic value for the clinical treatment of patients with COPD.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Salmeterol and formoterol are two commonly used drugs in COPD therapy, which act as β2-receptor agonists (8). Salmeterol and formoterol were identified as β2-receptor agonists that inhibit early and late phase antigen-induced airway hyper-responsiveness (9,10).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of salmeterol and formoterol combination treatment in mice with chronic obstructive pulmonary disease

Wang

Yang

2017

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…Different research groups have been focused on the key inflammatory regulators, such as inhibitors of phosphodiesterase-4 (PDE4), p38 mitogen-activated protein kinase (p38), and Janus kinases [10][11][12][13].…”

Section: Development Of New Drugs For Chronic Obstructive Pulmonary Dmentioning

confidence: 99%

Drugs for Treating Respiratory System Diseases

Vardanyan

Hruby

2016

Synthesis of Best-Seller Drugs

View full text Add to dashboard Cite

Economic evaluations of fluticasone-propionate/salmeterol combination therapy for chronic obstructive pulmonary disease: a review of published studies

Roberts

Borrego

Kharat

et al. 2016

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

This review identifies and evaluates the comprehensive reporting of peer-reviewed economic evaluations of the effectiveness of fluticasone-propionate/salmeterol combination (FSC) therapy for maintenance treatment of chronic obstructive pulmonary disease (COPD). Economic evaluations were included if published in English since 2003. Evaluation categories included in the review were cost-effectiveness, cost-utility, and cost-consequence analyses. FSC is cost-effective in comparison to short-acting bronchodilators (SABDs). Cost and outcome differences between FSC and other long-acting therapies were modest. Studies exhibited large variations in populations, designs and environment, limiting the ability to draw conclusions. Many new maintenance treatments for COPD have been approved since 2010. Most have yet to be compared to older treatments like FSC. Evaluations are needed that consider costs and outcomes from a societal perspective (e.g., patients' ability to keep working) and evaluations that include subgroup analyses to investigate differential impacts according to clusters of patient characteristics.

show abstract

Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease

Abstract: Until new forms of drug combinations are made available, the use of dual-therapy containing a LABA and ICS remain as the most logical and appropriate approach for the treatment of patients suffering from severe and very severe COPD with repeated exacerbations.

Cited by 3 publications

References 71 publications

Efficacy of salmeterol and formoterol combination treatment in mice with chronic obstructive pulmonary disease

Efficacy of salmeterol and formoterol combination treatment in mice with chronic obstructive pulmonary disease

Drugs for Treating Respiratory System Diseases

Economic evaluations of fluticasone-propionate/salmeterol combination therapy for chronic obstructive pulmonary disease: a review of published studies

Contact Info

Product

Resources

About